These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24324096)

  • 41. Antiemetic effectiveness and nausea and vomiting incidence during capecitabine and oxaliplatin chemotherapy.
    Chan A; Tan SH; Low XH; Yap KY
    Nurs Res; 2012; 61(6):405-12. PubMed ID: 22960588
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy.
    Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
    Gynecol Oncol; 2000 Jul; 78(1):43-6. PubMed ID: 10873408
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
    J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone.
    Hesketh PJ; Gandara DR; Hesketh AM; Edelman M; Webber LM; McManus M; Hainsworth JD
    Cancer J Sci Am; 1997; 3(3):180-3. PubMed ID: 9161784
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: a population-based study.
    Gomez DR; Liao KP; Giordano S; Nguyen H; Smith BD; Elting LS
    Cancer; 2013 Apr; 119(7):1428-36. PubMed ID: 23212885
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
    Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
    Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy.
    Iihara H; Fujii H; Yoshimi C; Yamada M; Suzuki A; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
    Int J Clin Oncol; 2016 Apr; 21(2):409-418. PubMed ID: 26475354
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Chemotherapy induced emesis: pathophysiology and prevention].
    Mailliez A; Bonneterre J
    Bull Cancer; 2010 Feb; 97(2):233-43. PubMed ID: 20051348
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center.
    Nolte MJ; Berkery R; Pizzo B; Baltzer L; Grossano D; Lucarelli CD; Kris MG
    J Clin Oncol; 1998 Feb; 16(2):771-8. PubMed ID: 9469369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of the compliance with antiemetic guidelines for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancy.
    Uchida M; Nakamura T; Shima T; Mori Y; Yoshimoto G; Kato K; Shimokawa M; Hosohata K; Miyamoto T; Akashi K
    Pharmazie; 2019 Apr; 74(4):250-254. PubMed ID: 30940311
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy.
    Mahendraratnam N; Farley JF; Basch E; Proctor A; Wheeler SB; Dusetzina SB
    Support Care Cancer; 2019 Dec; 27(12):4525-4534. PubMed ID: 30915567
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adherence to antiemetic guidelines and control of chemotherapy-induced nausea and vomiting (CINV) in a large hospital.
    Caracuel F; Muñoz N; Baños U; Ramirez G
    J Oncol Pharm Pract; 2015 Jun; 21(3):163-9. PubMed ID: 24598374
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey.
    Vidall C; Fernández-Ortega P; Cortinovis D; Jahn P; Amlani B; Scotté F
    Support Care Cancer; 2015 Nov; 23(11):3297-305. PubMed ID: 25953380
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk.
    Okuyama A; Nakamura F; Higashi T
    JAMA Oncol; 2017 Mar; 3(3):344-350. PubMed ID: 27812688
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of adherence to the guidelines for the management of nausea and vomiting induced by chemotherapy.
    França MS; Usón Junior PL; Antunes YP; Prado BL; Donnarumma Cdel C; Mutão TS; Rodrigues HV; Giglio Ad
    Einstein (Sao Paulo); 2015; 13(2):221-5. PubMed ID: 26154543
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement.
    Einhorn LH; Rapoport B; Koeller J; Grunberg SM; Feyer P; Rittenberg C; Aapro M
    Support Care Cancer; 2005 Feb; 13(2):112-6. PubMed ID: 15480812
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk factors of chemotherapy-induced nausea and vomiting in patients with metastatic colorectal cancer: a prospective cohort study (YCOG1301).
    Takei S; Ishibe A; Watanabe J; Watanabe K; Suwa Y; Suzuki S; Nakagawa K; Suwa H; Ota M; Ichikawa Y; Kunisaki C; Yamanaka T; Endo I
    Int J Colorectal Dis; 2020 Dec; 35(12):2323-2329. PubMed ID: 32860080
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential.
    Olver I; Clark-Snow RA; Ballatori E; Espersen BT; Bria E; Jordan K
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S33-6. PubMed ID: 20803222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.